Silibinin (20 weeks/day IP, daily for 4 weeks) was shown to reduce fasting glucose and insulin levels, reverse insulin resistance, improve liver steatosis by suppressing oxidative stress and NF‐KB activation (Salamone et al., 2012). Here, NFKB1 is linked to Insulin resistance.